IL1B and COVID-19: Although the role of the exacerbated inflammatory response in developing clinical complications in patients with COVID-19 has been recognized from the beginning, and therapies directed against inflammatory mediators such as IL-1β and IL-6 have been proposed, the results have not yet been conclusive [79, 80].